Medical Image Analysis Software Market to Reach US$ 6.3 Bn by 2031, Growing at 8.5% CAGR as AI-Powered Diagnostics Expand: New Report by Wissen Research

Wissen Research forecasts the global medical image analysis software market will expand from $4.2 billion in 2026 to $6.3 billion by 2031, an 8.5% CAGR, driven by higher imaging volumes, chronic-disease demand and adoption of AI-enabled radiology workflows. CT was the largest modality segment in 2025, while AI-based detection and localization is expected to be the fastest-growing function; North America leads the market and Asia-Pacific is projected to grow fastest. Recent activity includes Siemens Healthineers' $87 million imaging and oncology partnership with Vanderbilt University Medical Center, GE HealthCare's Mayo Clinic theranostics collaboration, and Philips' FDA-cleared AI-enabled Alturion ultrasound launch.

Analysis

This is not a near-term revenue catalyst; it reinforces a medium-term mix shift toward software, service, and workflow revenue for SHL, GEHC, and PHG. The economic prize is less the standalone AI license than controlling the imaging workflow and data layer: embedded applications raise equipment switching costs, support recurring revenue, and can improve lifetime account value across installed CT, MR, ultrasound, and oncology fleets. SHL has the clearest installed-base advantage, while GEHC's molecular-imaging and theranostics exposure gives it a differentiated route to monetization where quantitative imaging is directly tied to high-value treatment decisions.

The likely margin beneficiary is the incumbent able to bundle clinically validated tools into capital-equipment renewals; specialized AI vendors risk becoming feature suppliers rather than independent platform winners. That favors SHL and GEHC over smaller pure-play detection vendors unless those vendors secure reimbursement, exclusive clinical datasets, or distribution partnerships. PHG remains more exposed to execution risk: AI workflow adoption can support ultrasound differentiation, but it will not by itself offset a weak order cycle or normalize hospital capital budgets.

The consensus risk is extrapolating an addressable-market forecast into earnings acceleration. Hospital procurement remains gated by integration with PACS/RIS, cybersecurity review, demonstrated workflow savings, and reimbursement; consequently, deployments can lag regulatory clearance by 12-24 months. Watch order-book mix, software/service growth, and adjusted EBITA conversion rather than AI product announcements. A sustained deterioration in provider capex, slower software attach rates, or evidence that generative AI compresses standalone algorithm pricing would falsify the incumbent software-upside thesis.

Near term, the release is informational and unlikely to move liquid large caps. Over 1-3 months, earnings calls and order commentary should reveal whether AI is converting into paid software attach and backlog rather than pilot activity; over 6-18 months, recurring-software penetration could justify modest multiple expansion for SHL and GEHC if margins demonstrate operating leverage.

Key Decisions for Investors

• Maintain/add a 6-18 month long SHL position versus a short PHG pair: SHL's broader imaging installed base and enterprise workflow position should monetize AI attachment more reliably. Target 10-15% relative return; exit if SHL software/service growth decelerates for two consecutive quarters or PHG materially outgrows on comparable imaging orders.
• Accumulate GEHC on post-earnings weakness rather than chase the news, with a 9-15 month horizon. The trade requires evidence of accelerating digital/solutions revenue and stable segment margins; a 2027 guidance reset driven by hospital capex or molecular-imaging execution would invalidate it.
• Avoid treating AGFB or SECT.B as direct AI-beta expressions until disclosures show contract value, recurring revenue mix, and implementation economics. Set an alert for a large enterprise-imaging contract or software ARR disclosure; absent that data, the forecast alone does not establish earnings sensitivity.
• For event-driven exposure, monitor SHL and GEHC quarterly software attach rate, service backlog, and EBITA margin. Add only if paid AI deployments are translating into backlog/conversion; reduce if management emphasizes pilots, partnerships, or regulatory clearances without quantified revenue.